Form 8K Protalix Biotherapeutics Inc For: 5 January
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Protalix Biotherapeutics Inc (PLX)
Protalix Biotherapeutics Inc stock price, this page displays NYSE PLX stock exchange data. View the PLX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Protalix Biotherapeutics Inc real time stock price chart below.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PLX quote. (ISIN: US74365A3095)
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PLX quote. (ISIN: US74365A3095)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.990
2.105
52 wk Range
1.320
3.100
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.9902.105
52 wk Range
1.3203.100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PLX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.000
Upside
+431.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Protalix Company Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix Biotherapeutics Inc Earnings Call Summary for Q3/2025
- Protalix (PLX) reported Q3 2025 EPS of $0.03, missing forecasts by 57.14%, with revenue at $17.67M slightly below expectations; stock plunged 13.55% to $1.85 in premarket trading.
- Despite quarterly disappointment, nine-month revenue grew 24% YoY to $43.6M, with net loss improving to $1.1M from $3.6M in 2024; cash position remains strong at $29.4M.
- Company plans to initiate Phase II clinical trial for PRX-115 gout treatment before year-end, with top-line results expected in Q3 2027.
- CEO Dror Bashan positioned PRX-115 as a potential 'best-in-class therapy,' while CFO Gilad Memlock confirmed sufficient cash runway for at least 12 months to fund the upcoming trial.
Last Updated: 13-11-2025, 07:26 pm
Read Full TranscriptCompare PLX to Peers and Sector
Metrics to compare | PLX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.9x | 119.2x | −0.6x | |
PEG Ratio | 0.20 | −0.65 | 0.00 | |
Price/Book | 3.1x | 4.6x | 2.6x | |
Price / LTM Sales | 2.7x | 7.2x | 3.3x | |
Upside (Analyst Target) | - | 118.4% | 40.0% | |
Fair Value Upside | Unlock | −1.7% | 3.2% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.000
(+431.40% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
0.03 / 0.07
Revenue / Forecast
17.67M / 17.79M
FAQ
What Is the Protalix (PLX) Stock Price Today?
The Protalix stock price today is 2.070.
What Stock Exchange Does Protalix Trade On?
Protalix is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Protalix?
The stock symbol for Protalix is "PLX."
What Is the Protalix Market Cap?
As of today, Protalix market cap is 166.47M.
What Is Protalix's Earnings Per Share (TTM)?
The Protalix EPS (TTM) is 0.07.
When Is the Next Protalix Earnings Date?
Protalix will release its next earnings report on 11 Mar 2026.
From a Technical Analysis Perspective, Is PLX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Protalix Stock Split?
Protalix has split 2 times.
How Many Employees Does Protalix Have?
Protalix has 213 employees.
What is the current trading status of Protalix (PLX)?
As of 10 Jan 2026, Protalix (PLX) is trading at a price of 2.070, with a previous close of 2.000. The stock has fluctuated within a day range of 1.990 to 2.105, while its 52-week range spans from 1.320 to 3.100.
What Is Protalix (PLX) Price Target According to Analysts?
The average 12-month price target for Protalix is USD11, with a high estimate of USD12 and a low estimate of USD10. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +431.40% Upside potential.
What Is the PLX Premarket Price?
PLX's last pre-market stock price is 2.040. The pre-market share volume is 1,70,770.000, and the stock has decreased by 0.040, or 2.000%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.